| Literature DB >> 34054508 |
Małgorzata Gałązka-Sobotka1, Iwona Kowalska-Bobko2, Krzysztof Lach3, Aneta Mela4, Maciej Furman2, Iga Lipska5.
Abstract
Introduction: The main challenge of modern hospitals is purchasing medical technologies. Hospital-based health technology assessments (HB-HTAs) are used in healthcare facilities around the world to support management boards in providing relevant technologies for patients. Aim: This study was undertaken to update the existing body of knowledge on the characteristics of HB-HTA systems/models in the selected European countries. Insights gained from this study were used to provide an optimal approach for implementing HB-HTA in Poland. Materials and methods: Firstly, we carried out a systematic review in PubMed and embase. Secondly, we searched for gray literature via the AdHopHTA online handbook and the design book of the AdHopHTA project, as well as literature describing healthcare systems provided by the WHO. Then, we conducted in-depth interviews with HB-HTA experts from four countries. Finally, we selected ten countries from Europe and prepared frameworks for data collection and analyses.Entities:
Keywords: decision making; health technology assessment; hospital based health technology assessment; hospital management; innovative medical technologies
Year: 2021 PMID: 34054508 PMCID: PMC8155722 DOI: 10.3389/fphar.2020.594644
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
Analytical framework for data extractions.
| Analytical frame | Scope |
|---|---|
| HB-HTA unit organisational model | •Independent group |
| •Integrated-essential HB-HTA | |
| •Stand-alone HB-HTA unit | |
| •Integrated specialized HB-HTA unit | |
| Characteristics of HB-HTA unit and its interaction with other stakeholders | •Description of activities/interactions |
| Level of interaction with other stakeholders | •Internal (inside one country) |
| •External (between countries) | |
| Interaction Type | •Informal |
| •Formal | |
| •Voluntary | |
| •Mandatory | |
| Stakeholders involved in the interactions | •HB-HTA organisational level (stakeholders from various governance and management level, e.g., self-governmental bodies) |
| •Additional important actors involved and their role | |
| Additional information | •All other relevant details |
Source: Own study based on AdHopHTA Handbook.
Selected countries for the analysis of HB-HTA models.
| Country |
| Type of healthcare system |
|---|---|---|
| Switzerland | 68,060 | Decentralized |
| Spain | 39,715 | Decentralized |
| France | 45,342 | Deconcentrated |
| Italy | 41,830 | Decentralized |
| Denmark | 55,671 | Decentralized |
| Finland | 46,735 | Decentralized |
| Sweden | 53,208 | Decentralized |
| The Netherlands | 56,328 | Decentralized |
| Austria | 54,454 | Decentralized |
GDP per capita expressed taking into account the purchasing power parity correction (PPP).
Source: Own study based on https://data.worldbank.org/indicator/NY.GDP.PCAP.PP.CD?locations=AT-ES-NL-FR-SE-FI-DK-IT-CH.
Characteristics of the analyzed countries in terms of similarities and differences of HB-HTA systems.
| Country/ Category | National HTA agency | HB-HTA model | Source of financing | Stakeholders | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Typical HTA Agency at the national level | Independent group | Stand-alone | Integrated-essential | Integrated-specialised | Internally (from hospital funds) | Externally (scientific grants and regional funds) | National HTA Agency or equivalent | Payer/insurer or Ministry of Health | Regional governments (hospital district representatives) | |
| Switzerland—CHUV | — | ✓ | ✓ | ✓ | ||||||
| Switzerland—HUG | ✓ | ✓ | ||||||||
| Switzerland—EHNV | ✓ | ✓ | ✓ | |||||||
| Spain—HCB | — | ✓ | ✓ | ✓ | ||||||
| Spain—VR&VM | ✓ | ✓ | ✓ | |||||||
| Spain—HStJD | ✓ | ✓ | ✓ | |||||||
| France | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |||
| Italy | ✓ | ✓ | ✓ | ✓ | ✓ | |||||
| Denmark | — | ✓ | ✓ | ✓ | ✓ | |||||
| Finland | ✓ | ✓ | ✓ | ✓ | ✓ | |||||
| Sweden | ✓ | ✓ | ✓ | ✓ | ||||||
| The Netherlands | ✓ | ✓ | ✓ | ✓ | ✓ | |||||
| Austria | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||||
Internal hospital units operating as an “independent group” that informally supports managerial decisions on health technologies.
With highly specialized and formalized units within hospitals, operating without strong influences from other external stakeholders, such as national HTA agencies (currently the most frequent model in Europe).
Units with limited staff but capable of involving other stakeholders acting as allies in their HTA activities.
Units influenced by formal collaboration with the national or regional HTA agencies. Generally, the involvement of HB-HTA units in the technology adoption process is considered good practice and the HTA-based recommendations are closely followed by hospital decision-makers.
CHUV, Lausanne University Hospital; HUG, Geneva University Hospital; EHNV, The North Vaudois Hospital; HCB, The Hospital Clinic of Barcelona; VR&VM, the Virgen del Rocio and Virgen de la Macarena hospitals; HStDJ, the Hospital Sant Joan de Deu.
Strengths and weaknesses of each HB-HTA organisational model in the context of HTA implementation at Polish hospitals.
| Strengths | Weaknesses | |||
|---|---|---|---|---|
| Hospital perspective | Health care system perspective | Hospital perspective | Health care system perspective | |
| Independent group | •“Pioneers” advocating/ promoting HTA units at hospitals | •Meaning of bottom-up initiatives aligned with internal needs | •Unacknowledged importance of HB-HTA among hospital management | •The absence of activity in HB-HTA |
| •“Pioneers” promoting evidence-based medicine approach | •Consideration of managerial effectiveness | •Informal HTA process (high level of hospital latitude) | •Inability to compare practices | |
| •Low level of engagement by “Pioneers” contingent on competence and time capacity | ||||
| •Bias among clinicians with experience in national HTA | ||||
| •Promoting national HTA at the hospital level by clinicians (losing the hospital perspective) | ||||
| Integrated-essential HB-HTA unit | •Initiating lefts of competence in HB-HTA | •Positive pressure on external institutions with lower competency in HB-HTA | •Low general activity level in HB-HTA | •The absence of sufficiently standardized procedures enabling comparisons |
| •Synergies in resources and competence boosting the HB-HTA process and decision-making ability | •Initiating networking activity with others, e.g., hospital clinics | •Low level of formalization | •Limited outreach of HB-HTA | |
| •Promoting hospital managerial effectiveness | •Creating opportunity to compare HB-HTA reports | |||
| Stand-alone HB-HTA unit | •formalization of HB-HTA unit in the organization chart of a hospital | •Bolstering managerial effectiveness of the hospital | •Cost of running an HB-HTA unit | •Good practices limited to a particular hospital without outreach |
| •Capabilities in HB-HTA for hospital managers | •Potential promoting criterion for best managerial practices at hospitals | •Limiting autonomy of hospital managers in making investment decisions | •The absence of sufficiently standardized procedures enabling comparisons | |
| •Center of excellence for developing HB-HTA capabilities for healthcare professionals | •formalization of process adversely impacting the willingness to initiate investments in new technologies | |||
| Integrated-specialized HB-HTA unit | •More structured approach to making investment decisions | •Ability to compare cost-effectiveness of assessed technologies | •Formal established collaboration practices with the national HTA agency | •Integration with national HTA |
| •High specialization in assessment domains (e.g., economic evaluation of health technologies) | •Ability to identify good practices in HB-HTA | •High level of formalization in division of work within an HB-HTA unit | •High standardization of HB-HTA methodology and processes | |
| •Improving the managerial and financial effectiveness of a hospital | •Improving effectiveness of public resource allocation in the hospital sector | •Proliferation of organisational structure | ||
| •Potential criterion for more favourable tariffs related to healthcare services | •Higher administrative costs | |||
Authors’ own study based on: Sampietro-Colom, L., Lach, K., Cicchetti, A., Kidholm, K., Pasternack, I., Fure, B., Rosenmöller, M., Wild, C., Kahveci, R., Wasserfallen, J.B., Kiivet, R.A., et al., The AdHopHTA handbook: a handbook of hospital-based Health Technology Assessment (HB-HTA); Public deliverable; The AdHopHTA Project (FP7/2007-13 grant agreement nr 305018); 2015. Available from: http://www. adhophta.eu/handbook. Access online: May 25, 2020. L. Sampietro-Colom, and J. Martin (Eds.), Hospital-Based Health Technology Assessment: The Next Frontier for Health Technology Assessment (pp. 39–44). Springer. https://doi.org/10.1007/978-3-319-39205-9_4.